Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Five Key Questions for Board Meetings

As public companies conduct spring board meetings, no topic looms larger than the effects of the coronavirus pandemic and how it is transforming the global economy. The way your organization’s leadership navigates this period of change is likely to determine its overall health once things settle into the “new normal.” At Weaver, we are committed…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Five Key Questions for Board Meetings

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

As public companies conduct spring board meetings, no topic looms larger than the effects of the coronavirus pandemic and how it is transforming the global economy.

The way your organization’s leadership navigates this period of change is likely to determine its overall health once things settle into the “new normal.”

At Weaver, we are committed to ensuring that you are empowered to lead your organization to the best of your ability. We provide the information and insights you need to thoroughly prepare for your next board meeting, ask the right questions and determine appropriate plans of action based on the most critical unfolding topics and trends.

The following five questions can help guide your next board meeting so that you can respond to rapidly changing events in a productive and thorough way.

1. Do we have a plan for financial disclosures related to the effects of COVID-19?

The SEC has encouraged registrants to disclose the effect of the COVID-19 pandemic on their financial results. Regulatory relief is available for companies impacted by the coronavirus, but companies must file certain forms to qualify. SEC guidance for public companies also addresses disclosures surrounding changes to annual shareholder meetings and more.

2. Are we prepared for current and future supply chain disruptions?

Your supply chain is likely to have been affected by COVID-19. Whether or not you were prepared, now is the time to thoroughly assess possible lingering impacts, prepare for the likely economic downturn to come and agree on a plan to adjust to future disruptions. Find potential alternatives and develop creative and cost-effective ways to map your supply network. Take the pandemic into account when evaluating supplier performance and be proactive when planning for the future.

3. Are our IT systems secure?

Are you doing enough to protect your operations from cyber threats? Bad actors aren’t sympathetic to the stressors placed on your organization or business by the spread of COVID-19. In fact, they’re stepping up their efforts to try and take advantage of the chaos.

As remote work requirements rise and your incident response processes are strained, other factors like pandemic-specific phishing campaigns and more will further test your employees and your overall preparedness. Here are eight CIO considerations to take into account as you review your preparedness.

4. Are we considering ESG reporting in our reporting and planning?

Environmental, social and governance (ESG) reporting shows investors that your company is taking these issues into account and playing an active role in bringing these initiatives into their core strategies. If you do not disclose and communicate these efforts, your company will not be positioned to take advantage of potential future benefits for growth, access to capital and more.

Are you aware of market-driven ESG reporting frameworks that can ensure you’re communicating effectively? Is your board equipped to assist your company in better addressing ESG issues and taking advantage of accelerating ESG investing?

5. Is our business continuity plan up to date?

Determine how you’ll respond to COVID-19 at every level, accounting for staff absences and leave, employee education, the capabilities of your remote-oriented operations, public relations factors and more. Be sure to communicate this information through as many channels as possible to your workforce, shareholders and customers.

Weaver offers information and insights to prepare for your next board meeting. We can help you ask the right questions and determine appropriate plans of action based on topics and trends as they unfold. Subscribe to our monthly insights for articles and information to help you review your organization’s operations and prepare for change in an uncertain world.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512